Shore Capital Reiterates "Buy" Rating for AstraZeneca (LON:AZN)

Key Points

• Shore Capital has reaffirmed a "buy" rating for AstraZeneca (LON:AZN) with a price objective of £135 ($180.36), indicating a potential upside of 23.09% from the current stock price.
• Other analysts, including Berenberg Bank and Deutsche Bank, have set price targets of GBX 140 ($1.87) and £110 ($146.96), respectively, with varying ratings on AstraZeneca's stock.
• AstraZeneca's stock opened at £109.68 ($146.53) and has a market capitalization of £211.03 billion, with a PE ratio of 30.06 and a 52-week range between GBX 9,573.51 ($127.90) and £133.88 ($178.86).

Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN - Free Report) in a research report released on Tuesday morning, Marketbeat reports. They currently have a £135 ($179.00) price target on the biopharmaceutical company's stock.

Several other research analysts have also commented on AZN. Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a £110 ($145.85) price target on shares of AstraZeneca in a research note on Tuesday, July 8th. Berenberg Bank reissued a "buy" rating and issued a GBX 140 ($1.86) price target on shares of AstraZeneca in a report on Friday, May 16th.

AstraZeneca Stock Up 3.0%

AstraZeneca stock traded up GBX 340 ($4.51) during trading on Tuesday, reaching £114.98 ($152.45). 4,846,914 shares of the company's stock were exchanged, compared to its average volume of 11,290,953. The company's 50-day moving average is £105.44 and its two-hundred day moving average is £108.74. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93. AstraZeneca has a 52-week low of GBX 9,573.51 ($126.94) and a 52-week high of £133.88 ($177.51). The firm has a market cap of £221.23 billion, a price-to-earnings ratio of 31.52, a PEG ratio of 0.86 and a beta of 0.17.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.